Halozyme Therapeutics, Inc.
HALO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.21 | 0.39 | -0.80 | 0.07 |
| FCF Yield | 7.72% | 7.66% | 3.02% | 5.27% |
| EV / EBITDA | 11.35 | 13.84 | 28.71 | 24.76 |
| Quality | ||||
| ROIC | 22.84% | 16.84% | 12.60% | 41.52% |
| Gross Margin | 84.30% | 76.80% | 78.90% | 81.64% |
| Cash Conversion Ratio | 1.08 | 1.38 | 1.19 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.43% | 23.21% | 35.12% | 31.27% |
| Free Cash Flow Growth | 25.47% | 58.64% | -21.04% | 462.76% |
| Safety | ||||
| Net Debt / EBITDA | 2.12 | 3.06 | 4.03 | 2.93 |
| Interest Coverage | 30.48 | 17.99 | 15.79 | 36.66 |
| Efficiency | ||||
| Inventory Turnover | 1.12 | 1.51 | 1.39 | 1.51 |
| Cash Conversion Cycle | 412.22 | 322.79 | 343.75 | 309.68 |